Ahmet Emre Eşkazan

Akademik Profiller

1. 1
   Refining the risk stratification in advanced‐stage classical Hodgkin lymphoma: A critical analysis of clinical prediction modelsBritish Journal of Haematology
   2025
2. 2
   Unusual synchronous and metachronous association of hematologic neoplasms with gynecologic neoplasms: A case series and literature reviewInternational Journal of Gynecology & Obstetrics
   2025
3. 3
   Perioperative Management of Atypical Hemolytic Uremic Syndrome in a Patient on Maintenance Eculizumab Therapy: A Case Report and Review of the LiteratureNephron
   2025
4. 4
   rADAMTS13 in cTTP: a new standard of care?Blood
   2025
5. 5
   Comment on: “Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study” by Busque et al.Blood Cancer Journal
   2025
6. 6
   The validation of advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI) in Turkish patients with classical Hodgkin lymphomaAnnals of Hematology
   2025
7. 7
   Patient‐reported outcomes in Chinese patients with chronic myeloid leukemia receiving olverembatinib: Quality of life matters!Cancer
   2025
8. 8
   Complications of therapeutic plasma exchange: A retrospective, single‐center study of 2505 procedures performed in 338 patients over 15 yearsTherapeutic Apheresis and Dialysis
   2024
9. 9
   Does discontinuing bleomycin due to toxicity increase the risk of lymphoma progression? Real-life data from a homogeneous population of advanced stage Hodgkin lymphomaJournal of Chemotherapy
   2024
10. 10
    Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?Expert Review of Hematology
    2024

Yayın listesi ORCID kaydından alındı.